Table 5– Adverse events
IndacaterolSalmeterolPlacebo
Subjects n330333335
Patients with any adverse event(s)169 (51.2)152 (45.6)156 (46.6)
 COPD worsening60 (18.2)51 (15.3)65 (19.4)
 Nasopharyngitis24 (7.3)29 (8.7)21 (6.3)
 Upper respiratory tract infection
  Bacterial14 (4.2)3 (0.9)5 (1.5)
  Viral10 (3.0)3 (0.9)7 (2.1)
 Lower respiratory tract infection9 (2.7)13 (3.9)8 (2.4)
 Back pain7 (2.1)12 (3.6)6 (1.8)
  • Data are presented as n (%) unless otherwise stated. Most common events listed for ≥3% of patients in either indacaterol or salmeterol groups. COPD: chronic obstructive pulmonary disease.